The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

The US regulator has rejected GlaxoSmithKline's pulmonary disease drug Nucala in a potential new chronic ... unsurprising news in the wake of the committee’s earlier stance.

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for ...

In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...

London open The FTSE 100 is expected to open eight points higher on Monday, having closed down 0.49% on Friday at 8,308.61.